Compare iShares MSCI India ETF (INDA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Johnson & Johnson — how do they compare? iShares MSCI India ETF trades at $46.03 (market cap $5.73B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 107.9× iShares MSCI India ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 58 Days and Johnson & Johnson for 129 Days on average.
| INDA | JNJ | |
|---|---|---|
Market Cap | $5.73B | $618.09B |
Volume | 6,797,522 | 6,050,983 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $278.43 |
52-Week Low | $45.42 | $186.00 |
Typical Hold Time | 58 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $45.98, down 0.3% with bearish technical signals showing 19 sell indicators versus 5 buy signals. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and pharma sector export issues. Technical indicators show oversold conditions with RSI readings below 16, suggesting potential for near-term bounce despite the dominant bearish trend.
The outlook remains cautious as India's market composition with heavy banking sector exposure and external pressures from US tariff tensions create uncertainty. Key support at $45 provides critical technical level, while sector-specific challenges in technology and pharmaceuticals warrant careful monitoring of India's economic resilience.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
